Literature DB >> 30328620

Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies.

David A Mahvi1, Rong Liu2, Mark W Grinstaff3, Yolonda L Colson4, Chandrajit P Raut5.   

Abstract

Locoregional recurrence negatively impacts both long-term survival and quality of life for several malignancies. For appropriate-risk patients with an isolated, resectable, local recurrence, surgery represents the only potentially curative therapy. However, oncologic outcomes remain inferior for patients with locally recurrent disease even after macroscopically complete resection. Unfortunately, these operations are often extensive, with significant perioperative morbidity and mortality. This review highlights selected malignancies (mesothelioma, sarcoma, lung cancer, breast cancer, rectal cancer, and peritoneal surface malignancies) in which surgical resection is a key treatment modality and local recurrence plays a significant role in overall oncologic outcome with regard to survival and quality of life. For each type of cancer, the current, state-of-the-art treatment strategies and their outcomes are assessed. The need for additional therapeutic options is presented given the limitations of the current standard therapies. New and emerging treatment modalities, including polymer films and nanoparticles, are highlighted as potential future solutions for both prevention and treatment of locally recurrent cancers. Finally, the authors identify additional clinical and research opportunities and propose future research strategies based on the various patterns of local recurrence among the different cancers.
© 2018 American Cancer Society.

Entities:  

Keywords:  breast cancer; drug delivery; local recurrence; lung cancer; mesothelioma; nanoparticles; peritoneal surface malignancies; polymers; rectal cancer; sarcoma

Mesh:

Year:  2018        PMID: 30328620      PMCID: PMC6239861          DOI: 10.3322/caac.21498

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  137 in total

1.  Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.

Authors:  Irene L Wapnir; Stewart J Anderson; Eleftherios P Mamounas; Charles E Geyer; Jong-Hyeon Jeong; Elizabeth Tan-Chiu; Bernard Fisher; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

2.  Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group.

Authors:  G van Tienhoven; A C Voogd; J L Peterse; M Nielsen; K W Andersen; F Mignolet; R Sylvester; I S Fentiman; E van der Schueren; K van Zijl; M Blichert-Toft; H Bartelink; J A van Dongen
Journal:  Eur J Cancer       Date:  1999-01       Impact factor: 9.162

3.  Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group.

Authors:  Alessandro Gronchi; Dirk C Strauss; Rosalba Miceli; Sylvie Bonvalot; Carol J Swallow; Peter Hohenberger; Frits Van Coevorden; Piotr Rutkowski; Dario Callegaro; Andrew J Hayes; Charles Honoré; Mark Fairweather; Amanda Cannell; Jens Jakob; Rick L Haas; Milena Szacht; Marco Fiore; Paolo G Casali; Raphael E Pollock; Chandrajit P Raut
Journal:  Ann Surg       Date:  2016-05       Impact factor: 12.969

4.  Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation.

Authors:  A Katz; E A Strom; T A Buchholz; H D Thames; C D Smith; A Jhingran; G Hortobagyi; A U Buzdar; R Theriault; S E Singletary; M D McNeese
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

5.  Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma.

Authors:  Daniel R Gomez; David S Hong; Pamela K Allen; James S Welsh; Reza J Mehran; Anne S Tsao; Zhongxing Liao; Stephen D Bilton; Ritsuko Komaki; David C Rice
Journal:  J Thorac Oncol       Date:  2013-02       Impact factor: 15.609

Review 6.  Nanoparticles and targeted drug delivery in cancer therapy.

Authors:  Behdokht Bahrami; Mohammad Hojjat-Farsangi; Hamed Mohammadi; Enayat Anvari; Ghasem Ghalamfarsa; Mehdi Yousefi; Farhad Jadidi-Niaragh
Journal:  Immunol Lett       Date:  2017-07-29       Impact factor: 3.685

7.  Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence.

Authors:  J-J Hung; W-H Hsu; C-C Hsieh; B-S Huang; M-H Huang; J-S Liu; Y-C Wu
Journal:  Thorax       Date:  2009-03       Impact factor: 9.139

8.  Analysis of 1,067 cases of video-assisted thoracic surgery lobectomy.

Authors:  Min Suk Choi; Joon Suk Park; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Young Mog Shim; Kwhanmien Kim
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2011-04-14

Review 9.  The Toxicity of Nanoparticles Depends on Multiple Molecular and Physicochemical Mechanisms.

Authors:  Yue-Wern Huang; Melissa Cambre; Han-Jung Lee
Journal:  Int J Mol Sci       Date:  2017-12-13       Impact factor: 5.923

Review 10.  Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues.

Authors:  Kanika Madaan; Sandeep Kumar; Neelam Poonia; Viney Lather; Deepti Pandita
Journal:  J Pharm Bioallied Sci       Date:  2014-07
View more
  58 in total

1.  Circ_0008500 Knockdown Improves Radiosensitivity and Inhibits Tumorigenesis in Breast Cancer Through the miR-758-3p/PFN2 Axis.

Authors:  Deyou Kong; Dongxing Shen; Zhikun Liu; Jun Zhang; Jian Zhang; Cuizhi Geng
Journal:  J Mammary Gland Biol Neoplasia       Date:  2022-03-03       Impact factor: 2.673

2.  Post-treatment lung cancer patients: residual tumor, recurrence, and second primary tumor.

Authors:  Dante Luiz Escuissato; Danny Warszawiak
Journal:  J Bras Pneumol       Date:  2021-09-06       Impact factor: 2.624

3.  Paclitaxel-loaded expansile nanoparticles improve survival following cytoreductive surgery in pleural mesothelioma xenografts.

Authors:  Ngoc-Quynh Chu; Rong Liu; Aaron Colby; Claire de Forcrand; Robert F Padera; Mark W Grinstaff; Yolonda L Colson
Journal:  J Thorac Cardiovasc Surg       Date:  2020-01-13       Impact factor: 5.209

4.  Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4.

Authors:  Bo Lian; Hua Wei; Ruiyan Pan; Jingui Sun; Bo Zhang; Jingliang Wu; Xiujie Li; Guixiang Tian
Journal:  Int J Nanomedicine       Date:  2021-01-15

5.  Delivery of eupenifeldin via polymer-coated surgical buttresses prevents local lung cancer recurrence.

Authors:  Zeinab Y Al Subeh; Ngoc-Quynh Chu; Jeremy T Korunes-Miller; Lillian L Tsai; Tyler N Graf; Yin P Hung; Cedric J Pearce; Mark W Grinstaff; Aaron H Colby; Yolonda L Colson; Nicholas H Oberlies
Journal:  J Control Release       Date:  2021-01-21       Impact factor: 9.776

6.  Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence.

Authors:  Géraldine Luis; Adrien Godfroid; Shin Nishiumi; Jonathan Cimino; Silvia Blacher; Erik Maquoi; Coline Wery; Alice Collignon; Rémi Longuespée; Laetitia Montero-Ruiz; Isabelle Dassoul; Naima Maloujahmoum; Charles Pottier; Gabriel Mazzucchelli; Edwin Depauw; Akeila Bellahcène; Masaru Yoshida; Agnès Noel; Nor Eddine Sounni
Journal:  Redox Biol       Date:  2021-05-14       Impact factor: 11.799

7.  Long Noncoding RNA MLK7-AS1 Promotes Non-Small-Cell Lung Cancer Migration and Invasion via the miR-375-3p/YWHAZ Axis.

Authors:  Jingzhou Jia; Jiwei Sun; Wenbo Wang; Hongmei Yong
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

8.  TV-circRGPD6 Nanoparticle Suppresses Breast Cancer Stem Cell-Mediated Metastasis via the miR-26b/YAF2 Axis.

Authors:  Xiaoti Lin; Weiyu Chen; Fengqin Wei; Xiaoming Xie
Journal:  Mol Ther       Date:  2020-09-05       Impact factor: 11.454

Review 9.  Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer.

Authors:  Fanglong Wu; Jin Yang; Junjiang Liu; Ye Wang; Jingtian Mu; Qingxiang Zeng; Shuzhi Deng; Hongmei Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-06-10

10.  Evaluation of Liposomal and Microbubbles Mediated Delivery of Doxorubicin in Two-Dimensional (2D) and Three-Dimensional (3D) Models for Breast Cancer.

Authors:  Melek Aydın; Ekrem Özdemir; Zekiye Altun; Sevgi Kılıç; Safiye Aktaş
Journal:  Eur J Breast Health       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.